![](https://2c717466dc25cd7041c9-8eeda6a8ca964cf210ed223dbc947813.ssl.cf2.rackcdn.com/18879597-655096707-wolf-jpg-100x53.jpeg)
Werewolf Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update
– Preliminary data from the WTX-124 monotherapy dose-escalation arm of the ongoing Phase 1/1b clinical trial provide compelling early evidence of dose-dependent anti-tumor and biomarker activity – – Safety data indicate WTX-124 is generally well …